TMDX | NASDAQ
Next Earnings: Aug 16, 2026
Company Overview:
7.3 Year TMDX Performance Metrics:
Unlock All Reports & Research Dividend Stocks.
[lev_ptables no_sale]TMDX Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for TMDX
Based on past 7.3-year performance, here are TMDX growth metrics:
Share price CAGR of +20.75%
Dividend CAGR of +0%
Using TMDX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| TMDX (DRIP) | TMDX - No DRIP | |
|---|---|---|
| Current Price | $88.58 | $88.58 |
| Start Shares | 112.89 | 112.89 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 112.89 | 112.89 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $583.88 | $88.58 |
| Total Dividends | $0 | $0 |
| Final Value | $65,916 | $10,000 |
NOTE: Above numbers are our estimate based on TMDX's Dividend and Price CAGR over past 7.3 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
[lev_ptables no_sale]Company Info
TransMedics Group, Inc. (TMDX) had its IPO on 2019-05-02, and is trader on NASDAQ stock exchange.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
TMDX website: https://www.transmedics.com
